Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1175–1179. doi: 10.1128/aac.40.5.1175

Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.

J F Plouffe 1, M T Herbert 1, T M File Jr 1, I Baird 1, J N Parsons 1, J B Kahn 1, K T Rielly-Gauvin 1
PMCID: PMC163286  PMID: 8723461

Abstract

Community-acquired pneumonia occurs 3 to 4 million times per year in the United States, accounting for about 500,000 hospitalizations annually. Empiric treatment is usually instituted because of a lack of early organism-specific diagnostic tests. This study compared empiric therapy with ofloxacin to standard antibiotic regimens (usually a beta-lactam with or without a macrolide) for patients hospitalized for community-acquired pneumonia. Therapy was administered to 298 patients (146 receiving ofloxacin and 152 receiving standard therapy); 227 patients (ofloxacin, 109; standard treatment, 118) were evaluable for treatment efficacy. The most common pyogenic respiratory pathogens were Haemophilus influenzae (30 isolates) and Streptococcus pneumoniae (24 isolates). There was evidence of infection with either Mycoplasma pneumoniae (38 patients), Chlamydia pneumoniae (40 patients), or a Legionella sp. (8 patients) in a total of 79 patients (35%). The clinical success rates were similar in both groups among evaluable patients (92%, ofloxacin; 87%, standard therapy) and among patients with atypical respiratory pathogens (88%, ofloxacin; 81%, standard therapy). The mean numbers (+/- the standard deviations) of intravenous doses of antibiotics were 7.5 +/- 8.0 in the ofloxacin group and 18.4 +/- 18.5 in the standard therapy group (P < 0.001); the mean number of oral doses of ofloxacin per patient was 19.7 +/- 11.2, compared with 30.2 +/- 16.0 oral antibiotic doses in the standard therapy group (P < 0.001). All treatments were well tolerated and associated with no significant clinical or laboratory abnormalities. The findings of this study indicate that ofloxacin is active against traditional bacterial pathogens as well as the major atypical respiratory pathogens. When given as monotherapy for the empiric treatment of community-acquired pneumonia, ofloxacin is as effective as standard antimicrobial therapy.

Full Text

The Full Text of this article is available as a PDF (218.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashby B. L. Treatment of pneumonia: new strategies for changing pathogens. Clin Ther. 1991 Sep-Oct;13(5):637–650. [PubMed] [Google Scholar]
  2. Breiman R. F., Butler J. C., Tenover F. C., Elliott J. A., Facklam R. R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994 Jun 15;271(23):1831–1835. [PubMed] [Google Scholar]
  3. Cherubin C. E., Eng R. H., Smith S. M., Tan E. N. A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens. Diagn Microbiol Infect Dis. 1992 Feb;15(2):141–144. doi: 10.1016/0732-8893(92)90038-u. [DOI] [PubMed] [Google Scholar]
  4. Cundell D., Masure H. R., Tuomanen E. I. The molecular basis of pneumococcal infection: a hypothesis. Clin Infect Dis. 1995 Dec;21 (Suppl 3):S204–S211. doi: 10.1093/clind/21.supplement_3.s204. [DOI] [PubMed] [Google Scholar]
  5. Edelstein P. H. Antimicrobial chemotherapy for legionnaires' disease: a review. Clin Infect Dis. 1995 Dec;21 (Suppl 3):S265–S276. doi: 10.1093/clind/21.supplement_3.s265. [DOI] [PubMed] [Google Scholar]
  6. Fine M. J., Singer D. E., Hanusa B. H., Lave J. R., Kapoor W. N. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med. 1993 Feb;94(2):153–159. doi: 10.1016/0002-9343(93)90177-q. [DOI] [PubMed] [Google Scholar]
  7. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  8. Gentry L. O., Lipsky B., Farber M. O., Tucker B., Rodriguez-Gomez G. Oral ofloxacin therapy for lower respiratory tract infection. South Med J. 1992 Jan;85(1):14–18. doi: 10.1097/00007611-199201000-00005. [DOI] [PubMed] [Google Scholar]
  9. Gentry L. O., Rodriguez-Gomez G., Kohler R. B., Khan F. A., Rytel M. W. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis. 1992 Jan;145(1):31–35. doi: 10.1164/ajrccm/145.1.31. [DOI] [PubMed] [Google Scholar]
  10. Gleckman R. A. Oral empirical treatment of pneumonia. The challenge of choosing the best agent. Postgrad Med. 1994 Feb 1;95(2):165–172. [PubMed] [Google Scholar]
  11. Grayston J. T., Diwan V. K., Cooney M., Wang S. P. Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med. 1989 Jan;149(1):169–173. [PubMed] [Google Scholar]
  12. Grayston J. T., Kuo C. C., Wang S. P., Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986 Jul 17;315(3):161–168. doi: 10.1056/NEJM198607173150305. [DOI] [PubMed] [Google Scholar]
  13. Grayston J. T., Mordhorst C., Bruu A. L., Vene S., Wang S. P. Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1981-1983. J Infect Dis. 1989 Jun;159(6):1111–1114. doi: 10.1093/infdis/159.6.1111. [DOI] [PubMed] [Google Scholar]
  14. Håkansson A., Kidd A., Wadell G., Sabharwal H., Svanborg C. Adenovirus infection enhances in vitro adherence of Streptococcus pneumoniae. Infect Immun. 1994 Jul;62(7):2707–2714. doi: 10.1128/iai.62.7.2707-2714.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jorgensen J. H., Doern G. V., Maher L. A., Howell A. W., Redding J. S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990 Nov;34(11):2075–2080. doi: 10.1128/aac.34.11.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lipsky B. A., Tack K. J., Kuo C. C., Wang S. P., Grayston J. T. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990 Dec;89(6):722–724. doi: 10.1016/0002-9343(90)90212-v. [DOI] [PubMed] [Google Scholar]
  17. Lonks J. R., Medeiros A. A. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother. 1993 Sep;37(9):1742–1745. doi: 10.1128/aac.37.9.1742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Macfarlane J. T., Colville A., Guion A., Macfarlane R. M., Rose D. H. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet. 1993 Feb 27;341(8844):511–514. doi: 10.1016/0140-6736(93)90275-l. [DOI] [PubMed] [Google Scholar]
  19. Niederman M. S., Bass J. B., Jr, Campbell G. D., Fein A. M., Grossman R. F., Mandell L. A., Marrie T. J., Sarosi G. A., Torres A., Yu V. L. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993 Nov;148(5):1418–1426. doi: 10.1164/ajrccm/148.5.1418. [DOI] [PubMed] [Google Scholar]
  20. Plotkowski M. C., Puchelle E., Beck G., Jacquot J., Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis. 1986 Nov;134(5):1040–1044. doi: 10.1164/arrd.1986.134.5.1040. [DOI] [PubMed] [Google Scholar]
  21. Plouffe J. F., Breiman R. F., Facklam R. R. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA. 1996 Jan 17;275(3):194–198. doi: 10.1001/jama.275.3.194. [DOI] [PubMed] [Google Scholar]
  22. Plouffe J. F., File T. M., Jr, Breiman R. F., Hackman B. A., Salstrom S. J., Marston B. J., Fields B. S. Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin Infect Dis. 1995 May;20(5):1286–1291. doi: 10.1093/clinids/20.5.1286. [DOI] [PubMed] [Google Scholar]
  23. Sanders W. E., Jr, Morris J. F., Alessi P., Makris A. T., McCloskey R. V., Trenholme G. M., Iannini P., Bittner M. J. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med. 1991 Sep;91(3):261–266. doi: 10.1016/0002-9343(91)90125-h. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES